Resumen

MONTALVAN, Daniel Efraín Alejandro; FUENMAYOR, Carem Francelys Prieto  y  BENAVIDES, Rina Elizabeth Ortiz. Relation between the drug semaglutide and weight reduction in patients with obesity: a systematic review. Vive Rev. Salud [online]. 2022, vol.5, n.15, pp.698-714.  Epub 19-Oct-2022. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v5i15.181.

Pharmacological treatment for obesity is very limited; among those available on the market, Semaglutide, a subcutaneous ampoule applied weekly and used in patients with diabetes and obesity, stands out. Objective. To establish the relationship of Semaglutide as a potential drug for the treatment of obesity. Method. Descriptive study, mainly focused on the review and analysis of research published in scientific databases of high relevance, restricting only to publications from 2015 onwards (2022) that include as main topic the use of Semaglutide. Result. 802 records were identified in the databases, applying the selection criteria 45 articles were identified as potential sources of information, finally 15 articles were selected with highly relevant data for this review, where the dose of the drug for weight reduction was considered, it is observed that the greater the amount of Semaglutide a significant weight reduction is obtained, reaching a mean of 11.82 kg. Conclusion. Weekly treatment with Semaglutide administered subcutaneously with changes in eating style and physical activity, results in clinically relevant sustained weight loss over time, being able to reach applicability in patients whose treatment by other more conventional methods is not efficient.

Palabras clave : Anti-Obesity Agents; Obesity; Weight Loss; Glucagon-Like Peptides..

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )